Detect serotonin loss in Parkinson
- Trial ID
- NCT05516732
- Official Title
- Evaluation of Serotonergic Neurotransmission in Premotor and Motor Parkinson's Disease.
- Goal
- Detect serotonin loss in Parkinson
- Status
- RECRUITING
- Sponsor
- University of Exeter
- Study Type
- OBSERVATIONAL
- Enrollment
- 42 participants
- Conditions
- Parkinson Disease, Parkinson's, Parkinson's Disease, Neurodegenerative Diseases, Neurodegeneration, Positron Emission Tomography
- Interventions
- Positron Emission Tomography (PET) scan using CIMBI-36 tracer, Magnetic Resonance Imaging (MRI) Scan, Positron Emission Tomography (PET) scan using DASB tracer, FP-CIT Single-photon Emission Computed Tomography (SPECT) scan, Lumbar puncture
Plain-Language Summary
Trying to map how serotonin signalling changes before and after Parkinson's motor symptoms, and how those changes relate to dopamine loss and clinical features. The team uses PET with DASB to measure serotonin transporter availability and PET with CIMBI-36 to image 5-HT2A receptor binding, plus FP-CIT SPECT to measure dopamine transporter loss, MRI for anatomy, and lumbar puncture to collect CSF biomarkers. There is no experimental drug; the protocol is observational, but people on serotonin-active drugs like SSRIs are excluded and PD medications must be stable with no recent changes. Adults aged 25 to 85 who can tolerate PET and MRI scans and a lumbar puncture, who are not pregnant and who have not had PD surgery or are on advanced pump or apomorphine therapy, are being recruited.
Locations
- University Of Exeter, Exeter, Devon, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Positron Emission Tomography (PET) scan using CIMBI-36 tracer. Trying to map how serotonin signalling changes before and after Parkinson's motor symptoms, and how those changes relate to dopamine loss and clinical features. The team uses PET with DASB to measure serotonin transporter availability and PET with CIMBI-36 to image 5-HT2A receptor binding, plus FP-CIT SPECT to measure dopamine transporter loss, MRI for anatomy, and lumbar puncture to collect CSF biomarkers. There is no experimental drug; the protocol is observational, but people on serotonin-active drugs like SSRIs are excluded and PD medications must be stable with no recent changes. Adults aged 25 to 85 who can tolerate PET and MRI scans and a lumbar puncture, who are not pregnant and who have not had PD surgery or are on advanced pump or apomorphine therapy, are being recruited.
- Who can participate?
- Participants must be between 25 Years and 85 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 4 years.